The latest update is out from Synairgen ( (GB:SNG) ).
Synairgen plc has announced its intention to cancel the trading of its ordinary shares on AIM and re-register as a private limited company due to not meeting its Minimum Fundraising Condition. The company believes this move is in the best interest of its shareholders and has secured the support of its major shareholder, TFG Asset Management UK, which holds 86.9% of the ordinary shares. A general meeting has been scheduled for shareholder approval, and a secondary market trading facility will be provided post-cancellation to facilitate shareholder transactions.
More about Synairgen
Synairgen plc is a respiratory company based in Southampton, UK, focused on developing SNG001, an investigational inhalation formulation containing the broad-spectrum antiviral protein interferon beta.
YTD Price Performance: -26.11%
Average Trading Volume: 1,146,421
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £22M
For detailed information about SNG stock, go to TipRanks’ Stock Analysis page.